MeiraGTx Holdings (MGTX) Total Non-Current Liabilities (2017 - 2026)
MeiraGTx Holdings' (MGTX) quarterly Total Non-Current Liabilities came in at $248.8 million in Q4 2025, up 24.97% YoY from $199.1 million in Q4 2024, and up 8.82% on a QoQ basis from $228.7 million in Q3 2025.
Analysis
MeiraGTx Holdings (MGTX) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Total Non-Current Liabilities data on file, last reported at $248.8 million in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 24.97% year-over-year to $248.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $248.8 million (up 24.97% YoY) and the FY2025 annual result came in at $248.8 million, up 24.97% from the prior year.
- Total Non-Current Liabilities grew to $248.8 million in Q4 2025, from $228.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $248.8 million in Q4 2025 to a low of $108.4 million in Q2 2022.
- A 5-year average of $173.0 million and a median of $184.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities fell 9.03% — and 2023, when it soared 70.16%.
- Tracing MGTX's Total Non-Current Liabilities over 5 years: stood at $132.7 million in 2021, then jumped by 49.47% to $198.3 million in 2022, then declined by 6.13% to $186.2 million in 2023, then climbed by 6.95% to $199.1 million in 2024, then climbed by 24.97% to $248.8 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $248.8 million (Q4 2025), $228.7 million (Q3 2025), and $194.3 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | 179.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 179.22 Mn |
| Dec 31, 2025 | 248.82 Mn |
| Sep 30, 2025 | 228.66 Mn |
| Jun 30, 2025 | 194.30 Mn |
| Mar 31, 2025 | 189.57 Mn |
| Dec 31, 2024 | 199.10 Mn |
| Sep 30, 2024 | 200.87 Mn |
| Jun 30, 2024 | 184.12 Mn |
| Mar 31, 2024 | 185.06 Mn |
| Dec 31, 2023 | 186.17 Mn |
| Sep 30, 2023 | 172.99 Mn |
| Jun 30, 2023 | 184.44 Mn |
| Mar 31, 2023 | 195.68 Mn |
| Dec 31, 2022 | 198.32 Mn |
| Sep 30, 2022 | 176.66 Mn |
| Jun 30, 2022 | 108.39 Mn |
| Mar 31, 2022 | 124.30 Mn |
| Dec 31, 2021 | 132.68 Mn |
| Sep 30, 2021 | 113.58 Mn |
| Jun 30, 2021 | 119.15 Mn |